MORE | Spring 2025

Evaluation of a Novel Small Molecule Drug in Vascular Dysfunction

Atherosclerotic cardiovascular disease (ACVD), characterized by the buildup of plaques within blood vessels, remains the leading cause of morbidity and mortality worldwide. Current treatments manage risk factors but do not directly target vascular dysfunction and halt plaque progression. The Wang laboratory recently established a biomimetic nanoparticle platform, enabling site-specific delivery of therapeutic agents to plaques. This MORE project aims to utilize cellular and molecular biology techniques to assess the pharmacological impact of a novel small molecule drug in suppressing vascular dysfunction associated with ACVD. The findings will lay the groundwork for developing a targeted nanodrug for subsequent animal model testing.